BioSpace News Archive

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“RegeneRx”), today announced that it has entered into a definitive agreement with certain institutional and accredited investors, including certain directors and officers of the Company, in connection with a private placement of up to $2,000,000 of shares of its common stock and warrants at a purchase price of $0.20 per share and accompanying warrants

Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report its financial results for the third quarter of fiscal year 2021, the period ended May 31, 2021, after the close of the financial markets on Monday, July 12, 2021

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that the company completed submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the treatment of HIV-1 infection in heavily treatment-experienced (HTE) people with multi-drug resistant (MDR) HIV-1 infection.

Global Cord Blood Corporation, China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, announced its unaudited financial results for the fourth quarter and full year of fiscal 2021, ended March 31, 2021.

Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today commented on the recent decision by Health Canada to re-issue a Notice of Compliance (“NOC”) for Ruzurgi®

IDEX CORPORATION announced that it has scheduled the broadcast of the company’s second quarter earnings conference call over the Internet on Wednesday, July 28, 2021 at 9:30 a.m. CT.

BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTCQB:BVAXF) (“BioVaxys” or the “Company”) is pleased to announce a non-brokered private placement (the “Private Placement”) consisting of up to 9,090,909 units (“Units”) at a price of $0.22 per Unit for total gross proceeds of up to approximately $2,000,000.

Vorticom was engaged for an initial term of two years on January 16, 2019, which was extended effective September 1, 2020, for a successive 12-month period.

Broadening of Intellectual Property Portfolio for These Two NCES Clearly Defines Development Pathway for the Next Generation of Psychedelic Medicines to Treat Addiction

Movement Industries Corporation (OTC PINK: MVNT) (the “Company”) is excited to announce the product launch of iChem. iChem is a fully integrated SaaS (Software as a Service) product with a hardware platform based on cellular and satellite communications modules and allows monitoring and control of all chemical injection assets